Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721.

[1]  E. Slatopolsky,et al.  Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. , 1986, The Journal of clinical investigation.

[2]  J. Cheung,et al.  Calcium and ischemic injury. , 1986, The New England journal of medicine.

[3]  S. C. Garner,et al.  Circulating parathyroid hormone concentrations in normal and vitamin D-deprived rat pups determined with an N-terminal-specific radioimmunoassay. , 1986, Bone and mineral.

[4]  J. Bonjour,et al.  Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent. , 1985, The Journal of clinical investigation.

[5]  J. Bonjour,et al.  SUPPRESSION OF PARATHYROID SECRETION AFTER ADMINISTRATION OF WR‐2721 IN A PATIENT WITH PARATHYROID CARCINOMA , 1985, Clinical endocrinology.

[6]  L. Shaw,et al.  Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid. , 1985, Annals of internal medicine.

[7]  S. Goldfarb,et al.  Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells. , 1985, The Journal of clinical investigation.

[8]  Y. Berland,et al.  Effects of parathyroidectomy on bone formation and mineralization in hemodialyzed patients. , 1985, Kidney international.

[9]  R. Schrier,et al.  Protective effect of intrarenal calcium membrane blockers before or after renal ischemia. Functional, morphological, and mitochondrial studies. , 1984, The Journal of clinical investigation.

[10]  M. Gubler,et al.  Adverse effect of proteins on remnant kidney: dissociation from that of other nutrients. , 1983, Kidney international. Supplement.

[11]  S. Goldfarb,et al.  Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). , 1983, The New England journal of medicine.

[12]  S. Massry,et al.  Effect of parathyroid hormone on osmotic fragility of human erythrocytes. , 1982, The Journal of clinical investigation.

[13]  J. Yuhas.  Protective drugs in cancer therapy: optimal clinical testing and future directions. , 1982, International journal of radiation oncology, biology, physics.

[14]  H. Fleisch,et al.  Parathyroid hormone-independent adaptation of the renal handling of phosphate in response to renal mass reduction. , 1982, Kidney international.

[15]  L. Ibels,et al.  Calcification in end-stage kidneys. , 1981, The American journal of medicine.

[16]  S. Massry,et al.  Effect of parathyroid hormone on rat heart cells. , 1981, The Journal of clinical investigation.

[17]  M. Gubler,et al.  Effect of various protein diets on growth, renal function, and survival of uremic rats. , 1979, Kidney international.

[18]  L. Ibels,et al.  Preservation of function in experimental renal disease by dietary restriction of phosphate. , 1978, The New England journal of medicine.

[19]  J. Conger,et al.  Soft tissue calcification in chronic dialysis patients. , 1977, The American journal of pathology.

[20]  I. Clark,et al.  Prevention of Phosphate-induced Nephrocalcinosis by Parathyroidectomy 1 , 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[21]  A. Katz,et al.  SECONDARY HYPERPARATHYROIDISM AND RENAL OSTEO‐DYSTROPHY IN CHRONIC RENAL FAILURE: ANALYSIS OF 195 PATIENTS, WITH OBSERVATIONS ON THE EFFECTS OF CHRONIC DIALYSIS, KIDNEY TRANSPLANTATION AND SUBTOTAL PARATHYROIDECTOMY , 1969, Medicine.

[22]  J. Yuhas,et al.  Differential chemoprotection of normal and malignant tissues. , 1969, Journal of the National Cancer Institute.

[23]  D. Harris,et al.  Verapamil protects against progression of experimental chronic renal failure. , 1987, Kidney international.

[24]  J. Cheung,et al.  The Cellular Basis of Ischemic Acute Renal Failure , 1986 .

[25]  S. Klahr,et al.  Toxicity of parathyroid hormone in uremia. , 1986, Annual review of medicine.

[26]  J. Compston,et al.  Direct and indirect measurements of osteoid seam width in human iliac crest trabecular bone. , 1984, Metabolic bone disease & related research.

[27]  M. Dostál,et al.  Radioprotective and hemodynamic effects of WR-2721 and cystamine in rats: time course studies. , 1983, Neoplasma.

[28]  M. Kaye.  The effects in the rat of varying intakes of dietary calcium, phosphorus, and hydrogen ion on hyperparathyroidism due to chronic renal failure. , 1974, The Journal of clinical investigation.